Ads
related to: clinical trials for ovarian cancer
Search results
Results from the WOW.Com Content Network
It covered research on the detection, diagnosis, prevention, and treatment of ovarian cancer. Specific areas of interest included clinical research and mechanistic approaches, drug sensitivity and resistance , gene and antisense therapy, pathology, markers, and prognostic indicators, chemoprevention strategies, multimodality therapy, and ...
Promising results have been reported from a phase II clinical trial for ovarian cancer [5] and endometrial cancer. [6] Phase II trials have also been undertaken for prostate, breast and bladder cancer, although no results for these trials have been reported in peer-reviewed literature. A phase I trial in prostate cancer indicated that nine out ...
Having focused on research, the group had the first IOTA congress and the development of the IOTA website. Having established a platform of clinical research centres IOTA will be planning further studies investigating aspects of ovarian cancer management and outcome prediction.
Immunotherapy is a topic of current research in ovarian cancer. In some cases, the antibody drug bevacizumab, though still a topic of active research, is used to treat advanced cancer along with chemotherapy. [95] It has been approved for this use in the European Union. [120]
Talazoparib after trials for advanced hematological malignancies and for advanced or recurrent solid tumors. [27] it started in 2013 a phase III for metastatic germline BRCA mutated breast cancer. [28] Veliparib June 2014 in phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC). [29]
Farletuzumab (MORAb-003) is a humanized monoclonal antibody [1] of IgG1/κ [2] which is being investigated for the treatment of ovarian cancer. [3] [4] This drug was developed by Morphotek, Inc. It is targeted at folate receptor alpha (FRα) which is overexpressed in some cancers such as epithelial ovarian cancer (EOC) and non-small-cell lung ...
Ovarian Cancer Research Alliance (OCRA) is a not-for-profit organization focused on ovarian cancer research, advocacy and patient support. [1] The organization was formed in January 2016 when the former not-for-profit organization Ovarian Cancer Research Fund, which focused primarily on ovarian cancer research, combined with Ovarian Cancer National Alliance, which focused primarily on ovarian ...
A multicenter clinical trial, internationally known as MIMOSA (Monoclonal antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab), in which Abagovomab will be administered as maintenance therapy (after first line therapy with surgery and chemotherapy), is ongoing in patients with ovarian cancer.
Ads
related to: clinical trials for ovarian cancer